Clinical Trial Update: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Vidutolimod (CMP-001) in combination with Nivolumab versus Nivolumab alone in melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Vidutolimod (CMP-001) (Vidutolimod)
• nivolumab (nivolumab)

Snippet

Sponsor: Diwakar Davar | Conditions: Melanoma | Phase 2 | Status: COMPLETED